Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 31 Other hematologic neoplasm 2 Lymphoid 1

Conditions

Multiple Myeloma 1 Lymphoma 1

Interventions

Rituximab 376 Cyclophosphamide 179 Bendamustine Hydrochloride 109 obinutuzumab 100 Vincristine 94 fludarabine 92 ibrutinib 89 Prednisone 89 Doxorubicin 89 venetoclax 86 Lenalidomide 82 Gemcitabine 65 acalabrutinib 48 Brentuximab Vedotin 44 pembrolizumab 43 zanubrutinib 41 Dexamethasone 41 idelalisib 37 ofatumumab 32 Oxaliplatin 30 Chlorambucil 29 polatuzumab vedotin 25 blinatumomab 25 tocilizumab 24 Azacitidine 24 tositumomab I-131 22 Prednisolone 22 tisagenlecleucel 21 glofitamab 21 Nivolumab 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × elotuzumab × Lymphoid × Clear all

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡